JP2015508074A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508074A5 JP2015508074A5 JP2014556700A JP2014556700A JP2015508074A5 JP 2015508074 A5 JP2015508074 A5 JP 2015508074A5 JP 2014556700 A JP2014556700 A JP 2014556700A JP 2014556700 A JP2014556700 A JP 2014556700A JP 2015508074 A5 JP2015508074 A5 JP 2015508074A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- nhr
- nhc
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000006850 spacer group Chemical group 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 3
- 239000004471 Glycine Substances 0.000 claims 3
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 claims 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 3
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 3
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 3
- 239000004473 Threonine Substances 0.000 claims 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 3
- 235000004279 alanine Nutrition 0.000 claims 3
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims 3
- 235000008206 alpha-amino acids Nutrition 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 235000009697 arginine Nutrition 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000000732 arylene group Chemical group 0.000 claims 3
- 235000009582 asparagine Nutrition 0.000 claims 3
- 229960001230 asparagine Drugs 0.000 claims 3
- 235000003704 aspartic acid Nutrition 0.000 claims 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 3
- 235000013477 citrulline Nutrition 0.000 claims 3
- 229960002173 citrulline Drugs 0.000 claims 3
- 235000018417 cysteine Nutrition 0.000 claims 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 3
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 claims 3
- 235000013922 glutamic acid Nutrition 0.000 claims 3
- 239000004220 glutamic acid Substances 0.000 claims 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 3
- 235000004554 glutamine Nutrition 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000005549 heteroarylene group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- 229960000310 isoleucine Drugs 0.000 claims 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 3
- 229930182817 methionine Natural products 0.000 claims 3
- 229960003104 ornithine Drugs 0.000 claims 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 3
- 125000005717 substituted cycloalkylene group Chemical group 0.000 claims 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 3
- 239000004474 valine Substances 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- -1 azido, hydroxyl amino Chemical group 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- ZPWOOKQUDFIEIX-UHFFFAOYSA-N cyclooctyne Chemical compound C1CCCC#CCC1 ZPWOOKQUDFIEIX-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261598143P | 2012-02-13 | 2012-02-13 | |
| US61/598,143 | 2012-02-13 | ||
| US201261653785P | 2012-05-31 | 2012-05-31 | |
| US61/653,785 | 2012-05-31 | ||
| PCT/US2013/025247 WO2013122823A1 (en) | 2012-02-13 | 2013-02-08 | Enediyne compounds, conjugates thereof, and uses and methods therefor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508074A JP2015508074A (ja) | 2015-03-16 |
| JP2015508074A5 true JP2015508074A5 (https=) | 2016-02-18 |
| JP6113194B2 JP6113194B2 (ja) | 2017-04-12 |
Family
ID=47722570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014556700A Expired - Fee Related JP6113194B2 (ja) | 2012-02-13 | 2013-02-08 | エンジイン化合物、その抱合体、ならびにその使用および方法 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8709431B2 (https=) |
| EP (1) | EP2814829B1 (https=) |
| JP (1) | JP6113194B2 (https=) |
| KR (1) | KR101660146B1 (https=) |
| CN (1) | CN104220441B (https=) |
| AR (1) | AR089972A1 (https=) |
| AU (1) | AU2013221873B2 (https=) |
| BR (1) | BR112014019990A8 (https=) |
| CA (1) | CA2864420C (https=) |
| CL (1) | CL2014002096A1 (https=) |
| CO (1) | CO7061078A2 (https=) |
| CY (1) | CY1118899T1 (https=) |
| DK (1) | DK2814829T3 (https=) |
| EA (1) | EA027925B1 (https=) |
| ES (1) | ES2615268T3 (https=) |
| HK (1) | HK1204326A1 (https=) |
| HR (1) | HRP20170334T1 (https=) |
| HU (1) | HUE033704T2 (https=) |
| IL (1) | IL233965B (https=) |
| LT (1) | LT2814829T (https=) |
| MX (1) | MX350539B (https=) |
| PE (1) | PE20141791A1 (https=) |
| PL (1) | PL2814829T3 (https=) |
| PT (1) | PT2814829T (https=) |
| RS (1) | RS55763B1 (https=) |
| SG (1) | SG11201404667XA (https=) |
| SI (1) | SI2814829T1 (https=) |
| SM (1) | SMT201700137T1 (https=) |
| TW (1) | TW201336851A (https=) |
| WO (1) | WO2013122823A1 (https=) |
| ZA (1) | ZA201406723B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| KR20160068738A (ko) * | 2013-08-14 | 2016-06-15 | 윌리엄 마쉬 라이스 유니버시티 | 운시알라마이신의 유도체, 합성 방법 및 항종양 제제로서 이들의 용도 |
| CN106795214B (zh) | 2014-03-20 | 2022-09-02 | 百时美施贵宝公司 | 稳定化的基于纤连蛋白的支架分子 |
| MY189836A (en) | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| JP6668345B2 (ja) | 2014-11-21 | 2020-03-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 修飾された重鎖定常領域を含む抗体 |
| ES2981335T3 (es) | 2014-11-25 | 2024-10-08 | Bristol Myers Squibb Co | Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes |
| US10336766B2 (en) * | 2015-01-08 | 2019-07-02 | The Scripps Research Institute | Anticancer drug candidates |
| CN107406496A (zh) | 2015-03-10 | 2017-11-28 | 百时美施贵宝公司 | 可通过转谷氨酰胺酶缀合的抗体和由其制备的缀合物 |
| TN2019000101A1 (en) | 2015-05-29 | 2020-07-15 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof. |
| ES2809125T3 (es) | 2015-09-23 | 2021-03-03 | Bristol Myers Squibb Co | Moléculas de armazón a base de fibronectina de unión a glipicano-3 |
| JP6486316B2 (ja) | 2015-11-03 | 2019-03-20 | 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | 抗体−薬物複合体（ａｄｃ）およびそれを形成するための方法 |
| AU2016377371A1 (en) | 2015-12-21 | 2018-08-09 | Bristol-Myers Squibb Company | Variant antibodies for site-specific conjugation |
| KR20230038311A (ko) | 2016-03-04 | 2023-03-17 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd73 항체와의 조합 요법 |
| CN106267188B (zh) * | 2016-08-15 | 2025-06-17 | 深圳大学 | 小分子免疫激动剂偶联pd-1抗体的新型抗体及其在抗肿瘤中的应用 |
| WO2018048975A1 (en) | 2016-09-09 | 2018-03-15 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| IL270596B2 (en) | 2017-05-25 | 2026-01-01 | Bristol Myers Squibb Co | Antibodies containing heavy constant regions are adapted for use in cancer therapy |
| EP3720504A1 (en) * | 2017-12-06 | 2020-10-14 | Synaffix B.V. | Enediyne conjugates |
| CN110183659B (zh) * | 2018-02-21 | 2022-04-26 | 香港科技大学 | 含有杂环的聚合物、其制备方法及其应用 |
| EP3887397A1 (en) | 2018-11-28 | 2021-10-06 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| ES2943474T3 (es) | 2018-11-30 | 2023-06-13 | Bristol Myers Squibb Co | Anticuerpo que comprende una extensión carboxiterminal de una cadena ligera que contiene glutamina, conjugados del mismo, y métodos y usos |
| KR20210102334A (ko) | 2018-12-12 | 2021-08-19 | 브리스톨-마이어스 스큅 컴퍼니 | 트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도 |
| CN114174305A (zh) * | 2019-05-22 | 2022-03-11 | 德克萨斯大学系统董事会 | 用于治疗癌症的官能化的金卡宾萘醌络合物 |
| WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
| CN117794581A (zh) | 2021-06-28 | 2024-03-29 | 拜奥迪斯私人有限公司 | 包含磷酸抗原的缀合物及其在治疗中的用途 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4631190A (en) | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
| US5144011A (en) | 1981-06-26 | 1992-09-01 | Boston University | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4698420A (en) | 1985-02-25 | 1987-10-06 | Xoma Corporation | Antibody hybrid molecules and process for their preparation |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5281710A (en) * | 1990-08-01 | 1994-01-25 | The Scripps Research Institute | Dynemicin analogs: synthesis, methods of preparation and use |
| US5162330A (en) * | 1990-11-05 | 1992-11-10 | Bristol-Myers Squibb Co. | Dynemicin c antibiotic, its triacetyl derivative and pharmaceutical composition containing same |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US6955811B2 (en) | 1997-11-07 | 2005-10-18 | Trillium Therapeutics Inc. | Methods of inhibiting immune response suppression by administering antibodies to OX-2 |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7129261B2 (en) | 2001-05-31 | 2006-10-31 | Medarex, Inc. | Cytotoxic agents |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| EP1471938A4 (en) | 2002-01-09 | 2008-03-05 | Medarex Inc | HUMAN MONOCLONAL ANTIBODIES AGAINST CD30 |
| ATE459647T1 (de) | 2003-04-15 | 2010-03-15 | Glaxosmithkline Llc | Humane il-18 substitutionsmutanten und deren konjugate |
| GT200400138A (es) | 2003-07-22 | 2005-03-22 | Anticuerpos rgi y uso de los mismos. | |
| WO2005051976A2 (en) | 2003-11-20 | 2005-06-09 | Ansata Therapeutics, Inc. | Protein and peptide ligation processes and one-step purification processes |
| US8170637B2 (en) * | 2008-05-06 | 2012-05-01 | Neurosky, Inc. | Dry electrode device and method of assembly |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| JP4806680B2 (ja) | 2004-05-19 | 2011-11-02 | メダレックス インコーポレイテッド | 自己犠牲リンカー及び薬剤複合体 |
| RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| WO2007002223A2 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| CA2623236A1 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Human monoclonal antibodies to cd70 |
| BRPI0617546A2 (pt) | 2005-09-26 | 2011-07-26 | Medarex Inc | conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto |
| WO2007038868A2 (en) * | 2005-10-03 | 2007-04-12 | The University Of British Columbia | Novel enediyne compound and uses thereof |
| SI1940789T1 (sl) | 2005-10-26 | 2012-03-30 | Medarex Inc | Postopki in spojine za pripravo cc analogov |
| CA2627190A1 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| AU2006321553B2 (en) | 2005-12-08 | 2012-03-08 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to O8E |
| EA017812B1 (ru) | 2005-12-08 | 2013-03-29 | Медарекс, Инк. | Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение |
| KR100869414B1 (ko) | 2005-12-13 | 2008-11-21 | 야마하 가부시키가이샤 | 건반식 음판 타악기용의 음판 및 그 제조방법, 음판타악기의 음원 유닛 및 건반식 타악기 |
| EP2064316B1 (en) | 2006-09-08 | 2012-01-25 | Ambrx, Inc. | Site specific incorporation of non-natural amino acids by vertebrate cells |
| KR101552735B1 (ko) | 2006-12-01 | 2015-09-14 | 메다렉스, 엘.엘.시. | 씨디22에 결합하는 인간 항체 및 이의 용도 |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| TWI412367B (zh) | 2006-12-28 | 2013-10-21 | 梅達雷克斯有限責任公司 | 化學鏈接劑與可裂解基質以及其之綴合物 |
| CA2678514A1 (en) | 2007-02-21 | 2008-08-28 | Medarex, Inc. | Chemical linkers with single amino acids and conjugates thereof |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| CA2700860C (en) | 2007-10-01 | 2016-07-19 | Jonathan A. Terrett | Human antibodies that bind mesothelin, and uses thereof |
| WO2010087994A2 (en) | 2009-01-30 | 2010-08-05 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
-
2013
- 2013-02-08 KR KR1020147025070A patent/KR101660146B1/ko not_active Expired - Fee Related
- 2013-02-08 PT PT137048716T patent/PT2814829T/pt unknown
- 2013-02-08 HK HK15104893.3A patent/HK1204326A1/xx unknown
- 2013-02-08 SI SI201330469T patent/SI2814829T1/sl unknown
- 2013-02-08 PE PE2014001257A patent/PE20141791A1/es not_active Application Discontinuation
- 2013-02-08 DK DK13704871.6T patent/DK2814829T3/en active
- 2013-02-08 PL PL13704871T patent/PL2814829T3/pl unknown
- 2013-02-08 AU AU2013221873A patent/AU2013221873B2/en not_active Ceased
- 2013-02-08 EP EP13704871.6A patent/EP2814829B1/en active Active
- 2013-02-08 JP JP2014556700A patent/JP6113194B2/ja not_active Expired - Fee Related
- 2013-02-08 SG SG11201404667XA patent/SG11201404667XA/en unknown
- 2013-02-08 BR BR112014019990A patent/BR112014019990A8/pt not_active Application Discontinuation
- 2013-02-08 ES ES13704871.6T patent/ES2615268T3/es active Active
- 2013-02-08 AR ARP130100431A patent/AR089972A1/es unknown
- 2013-02-08 WO PCT/US2013/025247 patent/WO2013122823A1/en not_active Ceased
- 2013-02-08 CN CN201380019853.3A patent/CN104220441B/zh not_active Expired - Fee Related
- 2013-02-08 TW TW102105196A patent/TW201336851A/zh unknown
- 2013-02-08 CA CA2864420A patent/CA2864420C/en not_active Expired - Fee Related
- 2013-02-08 SM SM20170137T patent/SMT201700137T1/it unknown
- 2013-02-08 LT LTEP13704871.6T patent/LT2814829T/lt unknown
- 2013-02-08 HU HUE13704871A patent/HUE033704T2/en unknown
- 2013-02-08 EA EA201491447A patent/EA027925B1/ru not_active IP Right Cessation
- 2013-02-08 HR HRP20170334TT patent/HRP20170334T1/hr unknown
- 2013-02-08 MX MX2014009234A patent/MX350539B/es active IP Right Grant
- 2013-02-08 RS RS20170239A patent/RS55763B1/sr unknown
- 2013-02-11 US US13/764,226 patent/US8709431B2/en active Active
-
2014
- 2014-03-10 US US14/203,118 patent/US9156850B2/en active Active
- 2014-08-06 IL IL233965A patent/IL233965B/en active IP Right Grant
- 2014-08-07 CL CL2014002096A patent/CL2014002096A1/es unknown
- 2014-08-28 CO CO14189746A patent/CO7061078A2/es unknown
- 2014-09-12 ZA ZA2014/06723A patent/ZA201406723B/en unknown
-
2017
- 2017-03-03 CY CY20171100285T patent/CY1118899T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015508074A5 (https=) | ||
| HRP20170334T1 (hr) | Spojevi enedina, njihovi konjugati, primjene i metode | |
| JP2018503639A5 (https=) | ||
| JP2017095457A5 (https=) | ||
| JP2024040167A5 (https=) | ||
| JP2018502131A5 (https=) | ||
| JP2020536845A5 (https=) | ||
| JP2018537975A5 (https=) | ||
| JP2021510698A5 (https=) | ||
| JP2014517842A5 (https=) | ||
| JP2013532132A5 (https=) | ||
| JP2021532162A5 (https=) | ||
| JP2014506135A5 (https=) | ||
| WO2016106324A1 (en) | Organic anion transporting peptide-based cancer imaging and therapy | |
| RU2014146951A (ru) | Конъюгаты типа лиганд dr5-лекарственное средство | |
| HRP20211710T1 (hr) | Konjugacija specifična za mjesto spajanja lijekova za povezivanje s protutijelima i konjugati protutijela u lijeku koji nastaje kao rezultat | |
| JP2017512752A5 (https=) | ||
| JP2016521256A5 (https=) | ||
| FI3283521T3 (fi) | Lääkekonjugaatteja käsittäen vasta-aineita claudiinia 18.2 vastaan | |
| IL276514B1 (en) | Glypican 3 antibodies and conjugates thereof | |
| JP2018516851A5 (https=) | ||
| RU2018131636A (ru) | Новые конъюгаты аманитина | |
| WO2016077840A3 (en) | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use | |
| JP2017518304A5 (https=) | ||
| JP2017503777A5 (https=) |